Page results
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
Information about staff who work in the Macmillan Support and Information Service.
-
This information aims to support and supplement the information provided in the Be Active video available on uclh.nhs.uk/wellbeing
-
Health and wellbeing information for people affected by cancer.
-
This information explains when planned caesareans would be provided at The Whittington Hospital for women having antenatal care at UCLH.
-
Latest news and developments in the Macmillan Support and Information Service
-
Events, classes and workshops at the Macmillan Support and Information Service (MSIS)
-
This information page aims to answer some of the questions you may have about receiving chimeric antigen receptor (CAR) T-cell therapy at University College London Hospitals NHS Foundation Trust (UCLH).
File results
-
FOI/2022/0523 - Special Leave Policy - magistrate duties
-
FOI/2022/0525 - Prehabilitation services
-
FOI/2022/0527 - Staff data in Communications department
-
FOI/2022/0528 - Interpreting and translation services (Silent Sounds tender)
-
FOI/2022/0530 - Neonatal sepsis guidance
-
FOI/2022/0531 - Operating theatres in Trust
-
FOI/2022/0533 - Pathology service carrying out PCR testing for SARS-CoV2
-
FOI/2022/0539 - Pharmacological choices made for patients undergoing joint replacement surgery
-
FOI/2022/0557 - Patients treated with Visudyne (verteporfin)
-
FOI/2022/0563 - Ambulatory cardiac monitoring